1099.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 17:08):

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China...

Stats
本日の出来高	18.07M
平均出来高	5.10M
時価総額	63.00B
EPS	HKD0 ( 2024-04-25 )
Last Dividend	HKD0.901 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	6.45
ATR14	HKD0.0460 (0.23%)

ボリューム相関

長: 0.09 (neutral)

短: -0.43 (neutral)

Signal:(45.299) Neutral

SINOPHARM GROUP CO LTD 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

SINOPHARM GROUP CO LTD 相関 - 通貨/商品

-0.04
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.29
( neutral )

-0.69
( moderate negative )

0.05
( neutral )

SINOPHARM GROUP CO LTD 財務諸表

Annual	2023
収益:	HKD596.57B
総利益:	HKD48.51B (8.13 %)
EPS:	HKD2.90

FY	2023
収益:	HKD596.57B
総利益:	HKD48.51B (8.13 %)
EPS:	HKD2.90

FY	2022
収益:	HKD552.15B
総利益:	HKD47.43B (8.59 %)
EPS:	HKD4.60

FY	2021
収益:	HKD521.05B
総利益:	HKD44.05B (8.45 %)
EPS:	HKD2.49

Financial Reports:

No articles found.

SINOPHARM GROUP CO LTD Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.901 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

SINOPHARM GROUP CO LTD Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.69 - good (96.91%) | Divividend Growth Potential Score: 3.37 - Decrease likely (32.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0101	2010-04-29
Last Dividend	HKD0.901	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	14	--
Total Paid Out	HKD6.94	--
Avg. Dividend % Per Year	0.00%	--
Score	2.6	--
Div. Sustainability Score	9.69
Div.Growth Potential Score	3.37
Div. Directional Score	6.53	--

Next Divdend (Est)
(2025-04-07)

HKD0.958 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9909.HK	Ex Dividend Knight	2023-11-24	Semi-Annually	0.00%
2161.HK	Ex Dividend Junior	2023-08-15	Annually	0.00%
1161.HK	Ex Dividend Knight	2023-06-12	Annually	0.00%
0239.HK	Ex Dividend Knight	2023-09-29	Semi-Annually	0.00%
3866.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
1731.HK	Ex Dividend Junior	2023-06-23	Sporadic	0.00%
0771.HK	Ex Dividend Junior	2023-05-31	Sporadic	0.00%
2327.HK	Ex Dividend Junior	2023-08-03	Sporadic	0.00%
1290.HK	Ex Dividend Junior	2023-06-14	Sporadic	0.00%
0363.HK	Ex Dividend Knight	2023-06-01	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0155	1.500	9.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0358	1.200	8.81	10.00	[0 - 0.3]
returnOnEquityTTM	0.194	1.500	8.96	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.395	0.800	8.03	6.42	[1 - 3]
quickRatioTTM	1.034	0.800	8.63	6.90	[0.8 - 2.5]
cashRatioTTM	0.264	1.500	9.64	10.00	[0.2 - 2]
debtRatioTTM	0.188	-1.500	6.87	-10.00	[0 - 0.6]
interestCoverageTTM	20.69	1.000	3.45	3.45	[3 - 30]
operatingCashFlowPerShareTTM	23.49	2.00	2.17	4.34	[0 - 30]
freeCashFlowPerShareTTM	22.23	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.965	-1.500	6.14	-9.21	[0 - 2.5]
grossProfitMarginTTM	0.0838	1.000	-1.937	-1.937	[0.2 - 0.8]
operatingProfitMarginTTM	0.0381	1.000	-1.238	-1.238	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.017	1.000	5.46	5.46	[0.2 - 2]
assetTurnoverTTM	2.31	0.800	10.00	8.00	[0.5 - 2]
Total Score				9.69

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.31	1.000	9.67	0	[1 - 100]
returnOnEquityTTM	0.194	2.50	9.33	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	22.23	2.00	2.59	10.00	[0 - 30]
dividendYielPercentageTTM	4.75	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	23.49	2.00	2.17	4.34	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0825	1.000	-0.437	0	[0.1 - 0.5]
Total Score				3.37

SINOPHARM GROUP CO LTD

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.